Medtronic Launches Two New Clinical Programs to Evaluate the Use of Symplicity™1 Renal Denervation System across Multiple Conditions
Medtronic, Inc. (NYSE: MDT) announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company's Symplicity™ renal denervation system across multiple conditions. Furthering its leadership in the development of renal denervation therapy, Medtronic launched the Global SYMPLICITY Patient Registry, which will evaluate the real-world, long-term impact of renal denervation in more than 5,000 patients, as well as SYMPLICITY-HF, the first clinical trial to examine renal denervation in patients with chronic heart failure and renal impairment.
Renal denervation therapy is a minimally invasive, catheter-based procedure that modulates the output of nerves that line the walls of the arteries leading to the kidneys. These nerves impact the sympathetic nervous system, which affects the major organs that are responsible for regulating blood pressure: the brain, the heart, the kidneys and the blood vessels.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.